Upcoming Events

Food and Drug Administration (FDA) has approved several therapies specifically for lupus nephritis (LN). These drugs have been studied in clinical trials and shown to help protect kidney function [...]

If you follow lupus research, you may have heard about CAR-T cell therapy—an innovative treatment approach currently being investigated for people with complicated, refractory systemic lupus [...]

A liquid biopsy for kidney lupus is being developed. It relies on determining levels of tenascin C in the urine. It’s a predictor of kidney function loss in lupus. – Dr. Robert Katz, LSI's Board [...]

FDA approval based on superiority of Gazyva over standard therapy alone, as shown in Phase II NOBILITY and Phase III REGENCY data –

According to new research (Law, et. All, Nature, 2024), it may be that T lymphocytes appear to play a more important role than we thought in causing active lupus. They […]

Recent lupus research has received significant coverage bringing encouraging results.  The research was partially funded by the Lupus Research Alliance (LRA) – an organization the LSI [...]

By Dr. Robert Katz, LSI Board Chair and LSI Medical Advisory Board Chair (CAR T-cell therapy, typically used in cancer treatment, is a form of immunotherapy.In CAR T-cell therapy, blood […]

By Dr. Robert Katz Medical Advisory Board The effects of exercise intervention on health-related quality of life in patients with systemic lupus in the journal Healthcare. In this study, 1,058 [...]

By Dr. Robert Katz Medical Advisory Board Pharmacies are now offering booster shots for immunocompromised patients. Many lupus patients qualify because they are being treated with prednisone and [...]

By Dr. Robert Katz According to the CDC, the Delta variant of COVID-19 is more contagious – more than 2x as contagious as previous variants; some data suggest the Delta […]